[go: up one dir, main page]

AR065136A1 - Formas polimorficas de un inhibidor macrociclico de vhc. procesos de obtencion y composiciones farmaceuticas. - Google Patents

Formas polimorficas de un inhibidor macrociclico de vhc. procesos de obtencion y composiciones farmaceuticas.

Info

Publication number
AR065136A1
AR065136A1 ARP080100427A ARP080100427A AR065136A1 AR 065136 A1 AR065136 A1 AR 065136A1 AR P080100427 A ARP080100427 A AR P080100427A AR P080100427 A ARP080100427 A AR P080100427A AR 065136 A1 AR065136 A1 AR 065136A1
Authority
AR
Argentina
Prior art keywords
macrociclic
hchc
inhibitor
obtaining
processes
Prior art date
Application number
ARP080100427A
Other languages
English (en)
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065136(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of AR065136A1 publication Critical patent/AR065136A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula (1) en estado solido caracterizado por que se encuentra en forma cristalina.
ARP080100427A 2007-02-01 2008-02-01 Formas polimorficas de un inhibidor macrociclico de vhc. procesos de obtencion y composiciones farmaceuticas. AR065136A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07101563 2007-02-01

Publications (1)

Publication Number Publication Date
AR065136A1 true AR065136A1 (es) 2009-05-20

Family

ID=38229348

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080100427A AR065136A1 (es) 2007-02-01 2008-02-01 Formas polimorficas de un inhibidor macrociclico de vhc. procesos de obtencion y composiciones farmaceuticas.
ARP170101687A AR108819A2 (es) 2007-02-01 2017-06-19 Formas polimórficas de un inhibidor macrocíclico de vhc

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170101687A AR108819A2 (es) 2007-02-01 2017-06-19 Formas polimórficas de un inhibidor macrocíclico de vhc

Country Status (25)

Country Link
US (1) US8143402B2 (es)
EP (1) EP2118098B1 (es)
JP (1) JP5523110B2 (es)
KR (1) KR101580226B1 (es)
CN (3) CN105037347B (es)
AR (2) AR065136A1 (es)
AU (1) AU2008209696B2 (es)
BR (1) BRPI0806945A2 (es)
CA (1) CA2677170C (es)
CL (1) CL2008000321A1 (es)
CY (1) CY1116339T1 (es)
DK (1) DK2118098T3 (es)
ES (1) ES2524784T3 (es)
HK (1) HK1205125A1 (es)
HR (1) HRP20141137T1 (es)
IL (1) IL199215A (es)
MX (1) MX2009008275A (es)
NZ (1) NZ577568A (es)
PL (1) PL2118098T3 (es)
PT (1) PT2118098E (es)
RU (1) RU2533830C2 (es)
SI (1) SI2118098T1 (es)
TW (1) TWI423968B (es)
WO (1) WO2008092954A2 (es)
ZA (1) ZA200905377B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
EP3150596A1 (en) * 2009-02-27 2017-04-05 Janssen Pharmaceuticals, Inc. Amorphous salt of a macrocyclic inhibitor of hcv
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
KR101781789B1 (ko) 2010-01-27 2017-09-26 에이비 파르마 리미티드. C형 간염 바이러스 억제제로 사용되는 다환 헤테로사이클릭 화합물
EP2658858A4 (en) 2010-12-30 2014-06-25 Enanta Pharm Inc MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
KR20140022855A (ko) * 2011-05-04 2014-02-25 머크 샤프 앤드 돔 코포레이션 C형 간염 바이러스의 억제제의 제조 방법
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8962810B2 (en) 2011-06-16 2015-02-24 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
JP2014530177A (ja) 2011-09-16 2014-11-17 フオベア・フアルマシユテイカル アニリン誘導体、それらの調製およびそれらの治療適用
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
MX360452B (es) 2012-10-19 2018-11-01 Bristol Myers Squibb Co Inhibidores del virus de la hepatitis c.
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104995189B (zh) * 2014-01-21 2017-03-29 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CZ2015220A3 (cs) * 2015-03-27 2016-10-05 Zentiva, K.S. Amorfní sůl makrocyklického inhibitoru viru hepatitidy C
WO2016177625A1 (en) 2015-05-04 2016-11-10 Sandoz Ag Amorphous simeprevir potassium
CN105503851B (zh) * 2015-12-09 2017-06-23 重庆润生科技有限公司 一种烯基噻唑衍生物的制备方法
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1771050A (zh) * 2003-02-07 2006-05-10 益安药业 丙型肝炎丝氨酸蛋白酶的大环抑制剂
ATE497505T1 (de) * 2003-09-26 2011-02-15 Schering Corp Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
CN103145715B (zh) * 2003-10-14 2016-08-03 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
SI1713823T1 (sl) * 2004-01-30 2010-04-30 Medivir Ab Inhibitorji HCV NS-3 serin proteaze
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c

Also Published As

Publication number Publication date
KR20090115929A (ko) 2009-11-10
ES2524784T3 (es) 2014-12-12
CN105037347A (zh) 2015-11-11
CY1116339T1 (el) 2017-02-08
PT2118098E (pt) 2014-12-09
IL199215A (en) 2015-10-29
PL2118098T3 (pl) 2015-03-31
WO2008092954A3 (en) 2008-10-02
TW200846347A (en) 2008-12-01
HRP20141137T1 (hr) 2015-01-30
AU2008209696B2 (en) 2013-05-09
WO2008092954A2 (en) 2008-08-07
NZ577568A (en) 2012-02-24
RU2009132660A (ru) 2011-03-10
CA2677170C (en) 2017-04-18
JP2010517971A (ja) 2010-05-27
KR101580226B1 (ko) 2015-12-24
AR108819A2 (es) 2018-09-26
DK2118098T3 (en) 2014-12-08
JP5523110B2 (ja) 2014-06-18
EP2118098A2 (en) 2009-11-18
CA2677170A1 (en) 2008-08-07
MX2009008275A (es) 2009-08-12
HK1137438A1 (en) 2010-07-30
CN105037347B (zh) 2018-06-01
EP2118098B1 (en) 2014-09-24
HK1205125A1 (en) 2015-12-11
RU2533830C2 (ru) 2014-11-20
US20100029715A1 (en) 2010-02-04
US8143402B2 (en) 2012-03-27
SI2118098T1 (sl) 2015-01-30
CN101589040A (zh) 2009-11-25
BRPI0806945A2 (pt) 2014-05-06
CN104230918A (zh) 2014-12-24
CN104230918B (zh) 2018-01-26
WO2008092954A8 (en) 2009-12-23
CL2008000321A1 (es) 2008-08-22
ZA200905377B (en) 2010-10-27
AU2008209696A1 (en) 2008-08-07
TWI423968B (zh) 2014-01-21

Similar Documents

Publication Publication Date Title
AR065136A1 (es) Formas polimorficas de un inhibidor macrociclico de vhc. procesos de obtencion y composiciones farmaceuticas.
ECSP077984A (es) Formulacion de un inhibidor de agregacion de plaquetas de tienopiridina
CR7680A (es) Un nuevo proceso para la sintesis de agomelatina
EP1925676A4 (en) TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
ATE425138T1 (de) N-phenyl-phenylacetamid-nichtnukleosidinhibitor n reverser transkriptase
DK2504332T4 (da) Amorf form og krystallinsk form af genz 112638-hemitartrat som inhibitor af glucosylceramidsyntase
SMP200900023B (it) Benzossazoli e ossazolopiridine utili come inibitori di chinasi janus
ATE503744T1 (de) Nicht-nukleosidische reverse-transkriptase-hemmer
DE602004008227D1 (de) Inhibitoren dernicht-nukleosid-inhibitoren der reversen transkriptase
PL1928872T3 (pl) Nowe sulfonylopirole jako inhibitory HDAC
ATE459624T1 (de) Inhibitoren der reversen transkriptase des hiv
EP2201946A4 (en) HAMMER OF PAI-1 PRODUCTION
DK3330339T3 (da) Sammensætninger omfattende hfc-1234ze
EA201000257A1 (ru) Новый способ синтеза (7-метокси-l-нафтил) ацетонитрила и применение в синтезе агомелатина
DE602005017604D1 (de) Inhibitoren der nicht-nukleosid-inhibitoren der reversen transkriptase
CR11859A (es) Composición y proceso-356
ATE493485T1 (de) Hochtemperaturkorrosionsinhibitor
EA200500201A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
ITMI20050006A1 (it) Composizioni a base di oli perfluoropolieterei per la formazione di film lubrificanti
AR048235A1 (es) Un procedimiento para la sintesis de (7-metoxi-3,4-dihidro-1-naftalenil)acetonitrilo y su aplicacion en la sintesis de agomelatina
GT200900215A (es) Nuevo procedimiento de obtencion de la forma cristalina v de la agomelatina.
EP1910272A4 (en) Renin Inhibitors
EA200500204A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
EP1941906A4 (en) HEPATIC FIBROSIS HEMMER

Legal Events

Date Code Title Description
FC Refusal